Targeting DNA damage response and repair excluding PARP for triple negative breast cancer

Share :
Published: 17 May 2012
Views: 3933
Rating:
Save
Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden

Prof Helleday talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about novel therapies for triple negative breast cancer including the use of 6-mercaptopurine, previously not used in this group of patients.

The plan is to tackle cells which have been resistant to cisplatin or PARP inhibitors; Prof Helleday discusses studies underway.

 

Filming Supported by Amgen